Neuralstem, Inc. (NASDAQ:CUR) shares are climbing nearly 6% after announcing this morning it had entered into an official agreement with Tianjin Pharmaceutical Holding Group, …
Brean Capital analyst Difei Yang was out today with a few insights on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), following the news that the U.
Pfizer will acquire Medivation for $81.50 per share in cash- an offer unlikely to be bested, says Brean Capital
Brean Capital thinks Nike’s strategic supply chain partnership will become an important trend in meeting consumer demand
Brean Capital analyst Mike Burton was out raising the price target for Micron Technology, Inc. (NASDAQ:MU) to $18 (from $14), after the chip giant presented …
NVIDIA Corporation (NASDAQ:NVDA) released its fiscal 2017 second quarter results yesterday, which surpassed Street expectations, primarily driven by by strong Pascal GPU demand and rapid growth …
In a research report released Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Neuralstem, Inc. (NASDAQ:CUR), while slashing the …
In a research report issued Friday, Brean Capital analyst Difei Yang downgraded shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) from Buy to Hold, after the pharma …
In a research report released Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Heron Therapeutics Inc (NASDAQ:HRTX), with a …
In a research note issued yesterday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) with a price target of …